Baxter: Four-year Study Indicates Approx. 25% Lower Mortality With Use Of Theranova Dialyzer
Baxter International (BAX) announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
Peter Rutherford Baxter Theranova More Such Health News Baxter Renal Care Services Centers Baxter International Renal Care Services Centers
Source: rttnews.com